BiomX Inc. (PHGE)
NYSEAMERICAN: PHGE · Real-Time Price · USD
0.729
+0.001 (0.07%)
At close: Nov 4, 2024, 4:00 PM
0.710
-0.019 (-2.54%)
After-hours: Nov 4, 2024, 7:42 PM EST
Company Description
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease.
It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.
The company’s product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials.
BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
BiomX Inc.
| Country | Israel |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 71 |
| CEO | Jonathan Solomon |
Contact Details
Address: 22 Einstein Street, Floor 4 Ness Ziona, 7414003 Israel | |
| Phone | 972 7 2394 2377 |
| Website | biomx.com |
Stock Details
| Ticker Symbol | PHGE |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001739174 |
| CUSIP Number | 09090D103 |
| ISIN Number | US09090D1037 |
| Employer ID | 82-3364020 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jonathan Eitan Solomon MBA | Chief Executive Officer and Director |
| Marina Wolfson CPA | Chief Financial Officer and Secretary |
| Dr. Merav Bassan Ph.D. | Chief Development Officer |
| Prof. Rotem Sorek Ph.D. | Scientific Founder |
| Dr. Eran Elinav M.D., Ph.D. | Scientific Founder |
| Dr. Timothy K. Lu M.D., Ph.D. | Scientific Founder |
| Inbal Benjamini-Elran | C.H.R.O |
| Assaf Oron | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | 15-12G | Securities registration termination |
| Oct 28, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 25, 2024 | 25-NSE | Filing |
| Oct 15, 2024 | 8-K | Current Report |
| Sep 26, 2024 | 8-K | Current Report |
| Sep 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 16, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Jul 29, 2024 | 8-K | Current Report |